Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
The innovative drug maker’s stock jumped more than 18% in a single day on high hopes for inclusion of its blockbuster new drug, Nefecon, in China’s national reimbursement drug list…
Recent Articles
RELATED ARTICLES
-
Everest reaches new heights on growing drug sales
1952.HK - Health Guard plans dual listing to fund HPV vaccine fight
-
FAST NEWS: Everest Medicines loss widens on drug commercialization
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
